Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • ASTCT Pharmacy SIG Online Journal Club - May 2021

    Contains 1 Component(s) Includes a Live Web Event on 05/19/2021 at 3:00 PM (EDT)

    The Pharmacy SIG Online Journal Club session will be presented on May 19, 2021.

    The Pharmacy SIG Online Journal Club will be presented live on May 19, 2021 at 3pm ET/2pm CT.

    Presenters & Articles

    Jordyn Higgins, PharmD
    PGY-2 Oncology Pharmacy Resident
    Emory University Hospital Midtown/Winship Cancer Institute
    Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001):a multicentre seamless design study- Jordyn Higgins, PharmD (https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31366-0.pdf)

    Jordanne Adolphsen, PharmD
    PGY-2 Oncology Pharmacy Resident
    The University of Kansas Health System
    Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma (https://www.nejm.org/doi/full/10.1056/NEJMoa2024850 )

    Session Learning Objectives:
    Upon completion of the activity, participants should be able to:

    1. Discuss recent BMT pharmacy studies and their applications to current practice.
    2. Evaluate the safety and efficacy of liso-cel for the treatment of large B-cell lymphomas (LBCL).
    3. Assess the efficacy and safety of ide-cel in patients with triple exposed relapsed and refractory myeloma and to evaluate the pharmacokinetics, immunogenicity, and potential biomarkers for response and progression.

    Target Audience:
    This activity is intended for pharmacists.

    Accredited Provider:
    This activity is jointly provided by The France Foundation and ASTCT.

    Credit Designation:
    Pharmacists - The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award 1.0 CEU to pharmacists who complete the activity, complete the registration and evaluation forms, and successfully pass a posttest (>75%). There is no fee to participate in this activity. This is a knowledge-based educational activity. Your CE credits will be submitted electronically to the CPE Monitor. CE providers must upload participant information within 60 days from the date the participant completed the activity. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date.

    ACPE No. UAN: 0391-9999-21-160-L01-P.

    Disclosure Policy:
    In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

    Activity Staff Disclosures:
    The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

    The planners, reviewers, editors, staff, CME committee, or other members at the American Society for Transplantation and Cellular who control content have no relevant financial relationships to disclose.

    Faculty Disclosures:
    The faculty listed below report that they have no relevant financial relationships to disclose:

    • Jordyn Higgins, PharmD
    • Jordanne Adolphsen, PharmD

    Disclosure of Unlabeled Use:
    TFF and ASTCT require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

    Disclaimer:
    TFF and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and ASTCT assume no liability for the information herein.

    Contact Information:
    If you have questions about this CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

  • Utilizing A Comprehensive Team-Based Approach to Improving Patient-Important Outcomes After Transplant

    Contains 1 Component(s)

    This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.​

    Recent advancements in the care of stem cell transplant patients have improved outcomes including survival in this susceptible population. However, there are little data addressing patient-centered outcomes. Outcomes identified by patients and caregivers, termed patient-important outcomes, are crucial to foster health care focused not only on findings that are clinically pertinent but also on findings that are relevant to the patient. Understanding patient-important outcomes allows healthcare delivery systems to prioritize and standardize research, develop patient-important benchmarks and improve outcomes identified by patients. This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.

  • ASTCT Education Sessions at the 2021 TCT Meetings of ASTCT & CIBMTR

    Contains 11 Product(s)

    This package includes all 12 recordings of the ASTCT Education Sessions that were aired live during the 2021 TCT Meetings of ASTCT & CIBMTR.

    This package includes all 12 recordings of the ASTCT Education Sessions that were aired live during the 2021 TCT Meetings of ASTCT & CIBMTR. If you were already registered for TCT 2021, or if you have purchased access to all of the TCT Recordings via Confex, please email info@astct.org with proof of either purchase and we will supply you with a discount code to access this complete package for free!

  • Accelerating Aging: Considerations for Cellular Therapy and Transplantation

    Contains 1 Component(s)

    This session examines accelerated aging in the context of cellular therapy and transplantation and aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.​

    This session examines accelerated aging in the context of cellular therapy and transplantation. To foster an understanding of the role that cellular therapy and transplantation plays in older adults, barriers to treatment from patients’ and providers’ perspectives will be explored. Accelerated aging may be a limitation to proceeding to transplantation or cellular therapy and hamper recovery from this treatment. The session also focuses on the biopathophysiological mechanisms associated with accelerated aging in the context of cellular therapy and transplantation, physical and psychological manifestations of accelerated aging, and impact on survivorship. This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.

  • Individual Differences in Biobehavioral Mechanisms of Symptoms and HCT Outcomes: Current State of the Science

    Contains 1 Component(s)

    This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.​

    The interactions of behavioral, psychological, and socioenvironmental factors with biological processes (or ‘biobehavioral’) throughout the HCT trajectory significantly impact both psychological and physical morbidity and mortality. Stress-related factors have a well-documented impact on immune function among individuals with cancer and are especially salient in the HCT population given the nature of HCT recovery and survivorship. This sympsoium of the Biobehavioral Research Special Interest Group (SIG) of ASTCT provides an expert overview on the science of individual biobehavioral differences associated with symptoms and outcomes among HCT recipients. This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.

  • Thriving in Survivorship: Building Blocks for High-Quality Care

    Contains 1 Component(s)

    This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.​

    The Survivorship Special Interest Group is pleased to offer a multidisciplinary educational workshop focused on the survivorship and late effect needs of hematopoietic stem cell transplant (HCT) and cellular therapy survivors and their caregivers. As the number of HCT and cellular therapy survivors continues to increase in the coming years, it is essential that healthcare providers are equipped with the knowledge and skills to provide high-quality long-term care for this patient population and their caregivers. In this workshop, participants will have the opportunity to learn from experts in the field through presentations and in round table discussions on topics including, but not limited to the practical aspects of providing appropriate long-term follow-up and survivorship care, evolving telehealth modalities in survivorship care delivery, and development of a research program in HCT and cellular therapy survivorship. The session is open to physicians, advanced care practitioners, nurses, trainees, and other persons in Survivorship.  

  • Transplantation in Underrepresented Minority Communities

    Contains 1 Component(s)

    This session features a panel of experts discussing frequently overlooked topics related to transplantation in underrepresented minorities. This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.​

    This session features a panel of experts discussing frequently overlooked topics related to transplantation in underrepresented minorities. This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.

  • Snapshots from the COVID19 Pandemic in Transplant Centers Across the US

    Contains 1 Component(s)

    This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.​

    An expert panel of  experts in transplantation and infectious disease review their experience with the COVID pandemic in centers across the US. Panelists represent major geographic regions with emphasis in center size and location, patient diversity (adult/pediatric) and level of community spread of COVID19.  This session also discusses the scope and activities of TIC-SIG during the pandemic. This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.

  • Future of Chronic GVHD - 2020 NIH Chronic GVHD Consensus Project Recommendations

    Contains 1 Component(s)

    This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.​

    The content of this educational session covers reports and final recommendations of the four core working groups of the November 2020 NIH chronic GVHD consensus project. This latest work has been going on since 2019. Almost 100 expert scientists and academic clinicians representing national and international transplant community are contributing to this project which is aiming to fundamentally change our approaches to chronic GVHD therapy, prevention and research over next 5-7 years. This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.

  • Current Status in Chronic GVHD - Assessments and Choices in Clinical Practice

    Contains 1 Component(s)

    This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.​

    This practical hands on workshop aims to address the current status, therapeutic practices and common patient management dilemmas as recommended by leading clinical experts in the field of chronic GVHD. Currently there are no evidence based detailed clinical management guidelines for chronic GVHD which causes common dilemmas and differences across the wide range of practitioners at the university clinical centers, community hospitals or clinical practices. This session is based on the NIH criteria and how treatment options would look in 2021. This session will review common clinical scenarios and discuss situations considering the latest available evidence. This session aired as an ASTCT Education Session during the 2021 TCT Meetings of ASTCT & CIBMTR.